Skip to main content

Table 1 Patient Characteristics of the Total Rectal Cancer Cohort and stratified for HLA class I, HLA-G and Foxp3+ expression

From: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study

 

Total population n = 495

HLA Class I Loss n = 70 (15%)

HLA Class I Downregulationn = 105 (22%)

HLA Class I Expression n = 293 (63%)

HLA-G Weak n = 350 (72%)

HLA-G Strong n = 134 (28%)

Foxp3+ Below median n = 240 (50%)

Foxp3+ Above median n = 238 (50%)

Gender (%)

        

 Male

316 (63.8%)

49 (70.0%)

63 (60.0%)

186 (63.5%)

227 (64.9%)

83 (61.9%)

162 (67.5%)

142 (59.7%)

 Female

179 (36.2%)

21 (30%)

42 (40.0%)

107 (36.5%)

123 (35.1%)

51 (38.1%)

78 (32.5%)

96 (40.3%)

Age in years (mean SD)

64.5 (11.3)

64.8 (12.2)

65.5 (11.0)

64.0 (11.0)

64.7 (11.1)

63.9 (11.7)

64.7 (11.9)

(64.2 (10.5)

TNM stage (%)

        

 I

134 (27.1%)

9 (12.9%)

27 (25.7%)

89 (30.4%)

80 (22.9%)

50 (37.3%)

43 (17.9%)

85 (35.7%)

 II

136 (27.5%)

19 (27.1%)

25 (23.8%)

90 (30.7%)

98 (28.0%)

37 (27.6%)

65 (27.1%)

71 (29.8%)

 III

193 (39.0%)

33 (47.1%)

51 (48.6%)

96 (32.8%)

146 (41.7%)

41 (30.6%)

112 (46.7%)

72 (30.3%)

 IV

32 (6.5%)

9 (12.9%)

2 (1.9%)

18 (6.1%)

26 (7.4%)

6 (4.5%)

20 (8.3%)

10 (4.2%)

Tumor grade (%)

        

 Moderate

358 (72.3%)

41 (58.6%)

72 (68.9%)

228 (77.8%)

248 (70.9%)

102(76.1%)

160 (66.7%)

185 (77.7%)

 Poor

110 (22.2%)

23 (32.9%)

25 (23.8%)

54 (18.4%)

83 (23.7%)

25 (18.7%)

67 (27.9%)

40 (16.8%)

 Well

25 (5.1%)

5 (7.1%)

8 (7.6%)

10 (3.4%)

17 (4.9%)

7 (5.2%)

12 (5.0%)

12 (5.0%)

 Missing

2 (0.4%)

1 (1.4%)

 

1 (0.3%)

2 (0.6%)

 

1 (0.4%)

1 (0.4%)

Adjuvant therapy

        

 No

402 (81.2%)

46 (65.7%)

84 (80%)

253 (86.3%)

278 (79.4%)

116 (86.6%)

185 (77.1%)

205 (86.1%)

 Yes

75 (15.2%)

19 (27.1%)

19 (18.1%)

31 (10.6%)

58 (16.6%)

14 (10.4%)

44 (18.3%)

28 (11.8%)

 Missing

18 (3.6%)

5 (7.1%)

2 (1.9%)

9 (3.1%)

14 (4.0%)

4 (3.0%)

11 (4.6%)

5 (2.1%)

Circumferential margin

        

 Negative

397 (80.2%)

49 (70.0%)

83 (79.0%)

242 (82.6%)

279 (79.7%)

110 (82.1%)

188 (78.3%)

196 (82.4%)

 Positive

98 (19.8%)

21 (30.0%)

22 (21.0%)

51 (17.4%)

71 (20.3%)

24 (17.9%)

52 (21.7%)

42 (17.6%)

  1. This table shows the patient characteristics of the entire rectal cancer cohort (n = 495) and stratified for HLA class I, HLA-G and Foxp3+ staining.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us